Type 2 diabetes (T2D) remains a major cardiovascular (CV) risk factor [1] [2] [3] [4] [5] and it confers an approximately two-to threefold fold excess risk for coronary heart disease, including MI, stroke and heart failure (HF) in patients with and in patients without established cardiovascular disease (CVD). 1, [6] [7] [8] The prevalence of T2D among patients with HF is as high as 40-45% and that of HF in patients with T2D is reported to be 10-23%. 8 Patients with both conditions -regardless of ejection fraction -present a higher risk of hospitalisation for HF (HHF), all-cause and CV mortality, irrespective of ischaemic/non-ischaemic aetiology.
SGLT2 Inhibitors
Sodium-dependent glucose cotransporters (SGLTs) are responsible for tissular glucose translocation. SGLT1 is widely expressed in numerous organs (the distal S3 segment of the proximal renal tubule, intestines, heart and skeletal muscles), while SGLT2 is expressed in the luminal surface of the S1 segment of the proximal tubule and alfa-pancreatic cells. [17] [18] [19] The active transport of glucose via SGLT2 is linked to Na + transport maintained by its active extrusion via the Na + /K + ATPase of the basolateral membrane into the intracellular fluid. Under normal conditions, glucose is freely filtered into the urine at the glomerulus (180 g/day) and reabsorbed in the proximal tubuli by SGLT2 (90%) and SGLT1 (10%). 20 The plasma glucose concentration above which urinary glucose excretion occurs is approximately 180-200 mg/dl, but under diabetic conditions increases up to 300 mg/dl because of the increased activity of SGLT2.
SGLT2Is (canagliflozin, dapagliflozin, empagliflozin and ertugliflozin)
shift the renal tubular threshold for glycosuria to 50 mg/dl, reduce the reabsorption of filtered glucose (30-50%) and increase glycosuria, decreasing plasma glucose and HbA 1c levels independent of insulin. 17 Because glycosuria occurs only in the presence of hyperglycaemia, the risk of hypoglycaemia with SGLT2Is is low. Additionally, because Na + is co-transported with glucose, SGLT2Is cause an osmotic diuresis (increased urine output 107-450 ml/day) and a small natriuresis.
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Cardiovascular Outcomes Trials with SGLT2Is
Cardioprotective Effects
The effects of empagliflozin, canagliflozin and dapagliflozin were analysed in three CVOTs: EMPAgliflozin cardiovascular outcome event trial in type 2 diabetes mellitus patients -Removing Excess Glucose (EMPA-REG OUTCOME), the CANagliflozin cardioVascular Assessment
Study (CANVAS) Program and Dapagliflozin Effect on CardiovascuLAR
Events -Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58)
respectively ( Table 1) . [22] [23] [24] The EMPA-REG OUTCOME trial recruited patients with T2D and established CVD (secondary prevention). 22 Empagliflozin (pooled data of 10 and 25 mg doses) reduced the primary MACE outcome, an effect driven by a marked risk reduction in CV death (38%), without significant effects on atherosclerotic ischaemic events (nonfatal MI and nonfatal stroke). Additionally, empagliflozin significantly reduced all-cause, sudden and HHF. The reduction in HHF was observed in patients with and without documented HF at baseline and was associated to a reduction in the introduction of loop diuretics. 22, 25 The benefits were consistent among subgroups defined by baseline characteristics, including age, HbA 1c levels, BMI, estimated glomerular filtration rate (eGFR) or patients with versus without HF and across categories of medications to treat diabetes and/or HF. 22, [25] [26] [27] The CANVAS Program integrated 2 trials (CANVAS and CANVAS-Renal)
recruiting participants with T2D and established CVD (65.6%) or at risk for CV events (primary prevention). 23 Canagliflozin significantly decreased MACE and HHF to a similar extent to empagliflozin. However, none of the three individual components of MACE, nor all-cause mortality, were significantly reduced by canagliflozin. 23 Thus, it is difficult to understand what drives the superiority of canagliflozin for MACE over placebo. The benefit for the primary outcome was abrogated in patients without established CVD, suggesting that the benefit may be mostly in secondary prevention, while the point estimate for HHF was similar in both cohorts,
suggesting that this cardiac benefit may extended to diabetic individuals without overt CVD. Interestingly, the benefit on CV death or HHF may be greater in patients with a history of HF at baseline.
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The DECLARE-TIMI 58 trial recruited patients (40.6%) with established atherosclerotic CVD and with multiple risk factors for atherosclerotic CVD (59.4%). 24 Dapagliflozin met the pre-specified primary safety endpoint of noninferiority for MACE, but in the two primary efficacy analyses, it did not result in a significantly lower rate of MACE than placebo. However, dapagliflozin resulted in a lower rate of the other pre-specified primary efficacy outcome (the composite of CV death or HHF), which reflected a lower rate oh HHF, regardless of a history of atherosclerotic cardiovascular disease or HF.
Thus, SGLT2Is reduce HHF and exert cardioprotective effects in T2D
patients, but there were important differences between the CVOTs (Table 1) . First, almost all patients in the EMPA-REG OUTCOME trial received secondary prevention of CVD, while the CANVAS Program and DECLARE-TIMI 58 trial included patients who had or were at risk for atherosclerotic CVD (i.e. both primary and secondary prevention).
Second, HHF and mortality outcome curves begin to separate within the first 3 months in the EMPA-REG study but later in other CVOTs, i.e.
earlier than would be expected from any decrease in atherothrombotic events. [22] [23] [24] 30, 31 Third, only empagliflozin reduced both CV and all-cause mortality, probably because EMPA-REG OUTCOME was a secondary prevention trial and it is presumed that the higher the baseline risk for CV events the better the CV protection, while patients without CVD might require longer drug exposure to observe the benefits. 22 Finally, canagliflozin reduced the risk of nonfatal stroke, while a trend for an increased risk of stroke was observed with empagliflozin, which might be related to the higher CV risk of the population enrolled in EMPA-REG, including more patients with prior stroke (23% versus 19.3%). 32 In a post hoc analysis, this difference was attributed to events occurring >90 days after the last intake of study drug and driven by nonfatal ischaemic stroke, but there were no differences in the risk of recurrent, fatal, or disabling strokes, or transient ischaemic attacks, between empagliflozin and placebo. 32 
Renoprotective Effects
Chronic kidney disease (CKD) affects up to 40% of patients with T2D and increases mortality and morbidity. 33, 34 In the CVOTs, mean baseline eGFR
ranged between 76 and 85 ml/min/1.73m 2 but there were important differences in the percentage of patients with an eGFR <60 ml/min/ 1.73 m 2 or with macro/microalbuminuria ( Table 1) . Canagliflozin, dapagliflozin and empagliflozin showed a favourable effect on renal outcomes and slowed the progression of albuminuria and new onset or worsening nephropathy, even when the components of renal outcomes differ between CVOTs (Table 1) . 16, [22] [23] [24] 30, 31 In the EMPA-REG OUTCOME trial, where 25.9% of the population had CKD, the relative reductions in the risk of MACE, CV death, allcause mortality, and HHF were independent of eGFR down to 30 ml/ min/1.73m 2 or albuminuria status at baseline and similar across the two doses of empagliflozin versus placebo. 27 Similarly, in the CANVAS 
Because patients with lower eGFR at baseline are at an increased risk of HHF, the renoprotective effects of SGLT2Is may contribute to improved HF outcomes. 30, 31, 36, 37 
Mechanisms of Action
Multiple mechanisms are proposed to explain the early cardiorenal benefits of SGLT2Is [17] [18] [19] [20] 22, ( Figure 1 and Table 2 ). The early benefits observed in EMPA-REG OUTCOME and CANVAS Program cannot be explained by the modest changes in HbA 1c , blood pressure (BP), weight, visceral adiposity, uricaemia or haematocrit, alone or in combination,
suggesting that other glucose-independent mechanisms may contribute to the cardiorenal protective effects of SGLT2Is. 19, 30, 36, 37, 41, 55 In fact, the reduction in CV events related to glucose control appears only after many years of follow-up 17, 37 and in T2D patients antihypertensive therapy takes years to reduce major CV events, including nonfatal stroke and MI which remain unaltered with SGLT2Is. 17, 43, 44, 74 Three hypotheses have been proposed to explain the beneficial CV effects of SGLT2Is -the diuretic hypotheses, the thrifty substrate hypothesis and the NHE (Na + -H + exchanger) hypothesis.
The Diuretic Hypotheses
The early (<3 months) and significant reduction in HHF and CV mortality produced by empagliflozin in the absence of significant changes in the incidence of MI or stroke suggests that the predominant mechanism may relate to its haemodynamic effects. It has been hypothesised that the reduction in Na + and water retention, leading to reduced ventricular filling pressure and cardiac workload, could be an important mechanism. 30, [75] [76] [77] Indeed, an exploratory analysis of the EMPA-REG OUTCOME trial showed that changes in markers of plasma volume were the most important mediators of the reduction in the risk of CV death with empagliflozin versus placebo. 75 However, the diuretic effects of SGLT2Is are quite different from those observed with thiazide or loop diuretics. 77 The first reason for this is that SGLT2Is act in the proximal tubule, where they inhibit glucose and Na + reabsorption resulting in osmotic diuresis. However, compared with osmotic diuretics, SGLT2Is do not affect plasma osmolarity.
Second, because SGLT2Is work in the proximal tubule, they increase delivery of fluid and electrolytes to the macula densa, thereby activating tubuloglomerular feedback, an effect that is not achieved by loop and thiazide diuretics because they reduce Na + flux to the macula densa. 17, 69 Third, compared with loop diuretics, SGLT2Is produce a greater fluid clearance from the interstitial fluid space than from the circulation, potentially resulting in better congestion relief with minimal impact on BP, arterial filling and organ perfusion or inducing a neurohumoral activation. 78 Furthermore, SGLT2Is produce greater electrolyte-free water clearance than loop or thiazide diuretics acting at different sites of the nephron and producing more potent diuresis and natriuresis. 17, 20 Finally, loop diuretics reduce HHF but not CV mortality 69 
Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure
of these important differences, it is unlikely that SGLT2Is prevent HHF by acting simply as diuretics. 20, 37, 39 The Thrifty Substrate Hypothesis A shift in cardiorenal fuel energetics (the 'thrifty substrate' hypothesis). Under physiological conditions, nearly 95% of cardiac energy is derived from mitochondrial oxidative metabolism and fuel is derived from free fatty acids (FAs; 60-70%), glucose (30%) and -to a lesser degree -lactate, ketones and amino acids. 79 In T2D, glucose utilisation decreases while oxidation of FAs markedly increases because of peripheral insulin resistance and inability of insulin to suppress lipolysis. 37, 80, 81 These changes decrease cardiac efficiency/function because excessive FA oxidation is energetically less efficient, increases oxidative stress and cardiac lipotoxicity and impairs LVF. 37, 50, 80, 81 SGLT2Is increase the hepatic synthesis and decrease the urinary excretion of ketones producing a mild, [17] [18] [19] 22, [39] [40] [41] • Decrease plasma volume (cardiac preload) and total Na + tissue content
• SGLT2Is produce a greater fluid clearance from the interstitial space than from the circulation, resulting in better control of congestion without reducing arterial filling and tissue perfusion • Decrease ventricular preload and wall tension and elevated filling pressures • Counteract insulin-related fluid retention • These effects would reduce congestion, clinical decompensation and the risk of HHF BP reduction 19, 39, [42] [43] [44] • Due to osmotic diuresis and natriuresis and a reduction in intravascular volume and vascular stiffness, reduce BP (3.4-5.4/1.5-2.2 mmHg).
• Reduce afterload, intracardiac filling pressures and wall stress and may prevent clinical decompensation • Do not produce a reflex sympathetic activation Decrease arterial stiffness and PVR 40, 42, 45 • Arterial stiffness is a well-recognised predictor of CV morbidity and mortality • Due to weight loss, circulating volume contraction and vascular smooth muscle relaxation through a negative Na + balance
• Reduce PVR, BP and afterload, improve subendocardial blood flow and may contribute to reduce HHF Decrease body weight and visceral adiposity [17] [18] [19] 36, 37, 46 • Glycosuria results in caloric loss (240-400 Kcal/day) and body weight reduction (1.8-2.7 kg)
• Visceral adiposity is associated with adverse left ventricular remodelling, lower cardiac output and increased PVR Increase in haemoglobin and haematocrit levels 19, 39, 47 • Due to due osmotic diuresis and a transient increase in erythropoietin secretion • Improve myocardial/tissular oxygen delivery Anti-inflammatory and antioxidant effects 48, 49 • Reduce oxidative stress, pro-inflammatory and pro-oxidant biomarkers, decrease the formation of advanced glycation end products and improve endothelial function A shift in cardiac and renal fuel energetics 41, [50] [51] [52] [53] [54] [55] • Shift fuel energetics from FFA and glucose toward ketone bodies -Produce ATP energy more efficiently -Decrease myocardial and renal O 2 consumption -Reduce hypoxic stress on the diabetic heart and kidney -Increase cardiac work efficiency and function Metabolic effects 19, 36, 37, [54] [55] [56] • Decrease excess glucose uptake by the heart • Release glucagon which increases hepatic ketogenesis and exerts positive cardiac inotropic and chronotropic effects • Produce an uricosuric effect via the glucose transporter member 9 (GLUT9) and decrease uric acid levels • Increase LDL-/HDL-cholesterol and reduce triglyceride plasma levels Cardioprotective effects 19, 36, 37, 41, 50, [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] • Inhibit NHE3
• Reduce intracellular Na + and Ca 2+ load and increase mitochondrial Ca Heart Failure and Arrhythmias Even when SGLT2 is not expressed in the heart, SGLT2Is can inhibit cardiac NHE1, possibly through a binding site for SGLT2 on NHE1. 55 84 This finding suggests that empagliflozin promotes a reverse remodelling, which may contribute to the early cardiovascular and HF benefits observed in the EMPA-REG OUTCOME trial.
However, several questions remain unanswered, including the mechanism underlying the increase in BHOB, the time course of the hyperketonaemia, the relationship between the dose, hyperketonaemia and improvement in cardiac function, or whether hyperketonaemia might increase the risk of diabetic ketoacidosis (DKA). 59, 79, 83, 84 Additionally, an increase in metabolic efficiency and/or NHE inhibition should prove beneficial in myocardial ischaemia and HHF, but in CVOTs these two endpoints were differentially affected by SGLT2Is. 50, 79 Thus, at the present time, the 'thrifty substrate' hypothesis needs to be demonstrated. 83 
Renal Effects
In patients with T2D, glucose and Na + reabsorption increases in the proximal tubule via SGLT2 and Na + delivery to the macula densa decreases, which stimulates renin release by the juxtaglomerular cells and activates the RAAS. This causes, via tubuloglomerular feedback, an afferent arteriolar vasodilation that increases the GFR ('hyperfiltration') and contributes to diabetic nephropathy. SGLT2Is
reduce Na + reabsorption in the proximal tubule and increase its delivery to the macula densa. 19, 20, 69, 73, 85 
Adverse Events
SGLT2Is are generally well tolerated and adverse events (AEs) are considered mild-to-moderate in severity. [18] [19] [20] [22] [23] [24] 36, 37, 83, [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] However, some serious AEs have been reported in postmarketing surveillance programs ( Table 3 ). In the CANVAS Program, canagliflozin significantly increased the risk of fractures and below-knee lower extremity amputations. 23, 95 In the EMPA-REG trial, amputations and fractures
were not mentioned in the study protocol, but a post-hoc analysis reported a similar rate of both AEs with empagliflozin or placebo. 26, 55 However, EMPA-REG and CANVAS were not powerful enough to detect significant differences in either amputation or fracture among the studied population. Recently, several real-world studies have led to contradictory conclusions on the risk of amputations [90] [91] [92] 94 and a meta-analysis failed to demonstrate an increase in fracture events with SGLT2Is. 96 Therefore, it remains unclear whether the risk of these AEs extends across the drug class. Early trials raised the concern that SGLT2Is may increase the risk of bladder and breast cancer, and a meta-analysis suggested an increased risk of bladder cancer with empagliflozin. 100 However, given the short-term follow-up and uncertainty of evidence, future long-term prospective studies and postmarketing surveillance studies are warranted.
Unresolved Issues
Many questions remain to answered in future preclinical studies and carefully designed controlled trials ( Table 4) .
What are the mechanisms underlying the early cardiorenal benefits of Diabetic ketoacidosis 19, 36, 37, [87] [88] [89] • Appears with mildly elevated glucose levels (<13.9 mmol/L) which can delay diagnosis and therapy • Osmotic diuresis may worsen the hypovolaemic state of DKA, particularly in patients with nausea and decreased oral intake • Risk factors: hypovolaemia, acute illness or surgery, alcohol abuse, carbohydrate restriction, low insulin secretory capacity, increased glucagon secretion, previous episodes of ketosis, latent autoimmune diabetes in adults and T1D (SGLT2 are not approved for use) • SGLT2Is should be stopped during acute illness and at least 48 h before any planned surgical procedure • SGLT2Is are contraindicated in patients with DKA Lower-limb amputations 23, 28, 29, [90] [91] [92] [93] [94] • Canagliflozin may increase the risk of lower limb (toe or metatarsal) amputations.
• SGLT2Is produce haemoconcentration and volume depletion and decrease in BP, effects that may reduce limb perfusion and produce tissue ischaemia. Canagliflozin activates AMP kinase, which inhibits complex I of the respiratory chain and favours tissue ischaemia • Risk factors: men, prior history of lower-limb amputation, advanced peripheral vascular disease, peripheral neuropathy, and diabetic foot ulcers.
• EMA recommends careful monitoring of all patients receiving SGLT2Is, emphasising foot care. Consider stopping treatment if patients develop lower-extremity infections, new pain or tenderness, sores, ulcers, infection, osteomyelitis, or gangrene.
• Avoid canagliflozin (all SGLT2Is) in patients at the highest amputation risk until more safety data are accumulated Bone fractures [95] [96] [97] [98] [99] • Canagliflozin (not empagliflozin or dapagliflozin) increases the rate of all-bone and low-trauma fractures within the first weeks of treatment • Independent of changes in bone mineral density or alterations in calcium homeostasis Is the cardiorenal benefit a class effect? A class effect would not be expected if the underlying mechanisms are unrelated to SGLT2 inhibition.
There are differences among SGLT2Is in their SGLT2/SGLT1 selectivity (>2,500 for empagliflozin, 1,116 for dapagliflozin, 250 for canagliflozin), pharmacokinetic properties and -possibly -pharmacodynamic offtarget properties [17] [18] [19] 36, 37, 102 Thus, there is no evidence that the benefits can be a 'class effect'. Indeed, the FDA and European Medicines
Agency approved all SGLT2Is for glycaemic control in adults with T2D.
Additionally, empagliflozin is also approved to reduce the risk of CV death in adults with T2D and established CVD, and canagliflozin to reduce the risk of MACE in adults with T2D and established CVD.
How can the marked differences observed in CVOTs among SGLT2Is
be explained? 1 and white participants had better CV benefits than black participants in the EMPA-REG study, whereas canagliflozin was superior in black and white participants. 22, 23 These findings suggest that the benefits of SGLT2Is may depend on the population in which they are used.
What is the real benefit of SGLT2Is in patients with HF? CVOTs were not designed to assess the efficacy of SGLT2Is in patients with HF. Indeed, existing CVD, and with reduced CV mortality in patients with T2D and a broad cardiovascular risk profile. [103] [104] [105] [106] Therefore, the benefits observed with empagliflozin and canagliflozin may be a class effect applicable to a broad population of patients with T2D in real-world practice, including in primary prevention.
However, because of the observational design, short follow-up and immortal time and time-lag biases, the >50% lower rates of all-cause mortality associated with the use of SGLT2Is in these trials are more likely exaggerated. 107 Additionally, in these trials only 25% of patients presented established CVD, most were treated with canagliflozin and dapagliflozin (not with empagliflozin) and drug safety was not reported.
Thus, at the present time there is not enough evidence to extrapolate the data from the CVOTs to the real-world setting. 107 What is the risk/benefit ratio of SGLT2Is in the real world? Optimal prescription of SGLT2Is requires the understanding of their risk/benefit ratio, but AEs should not overshadow their cardiorenal protective effects. Some serious AEs were not observed in CVOTs, possibly because of the short follow-up and the selection and strict supervision • Where is SGLT2 expressed in the heart, vessels, kidney and peripheral and central nervous system controlling cardiovascular functions?
• The putative mechanisms of action of SGLT2Is should be validated in in vivo models and patients with and without T2D, and in those with HF with reduced or preserved ejection fraction.
• Are the mechanisms of action comparable across SGLT2Is or specific to individual compounds?
• Are there ethnic variations in the response to SGLT2Is? 2. Is the cardiovascular and renal benefit a class effect?
• Head-to-head comparisons among SGLT2Is are needed, but they will probably never be performed. in patients with T2D and HF. In the EMPA-REG OUTCOME trial, the effect of empagliflozin on HHF was reduced by mineralocorticoid receptor antagonists, which only represented 6% of patients in this trial, but are used in >60% of HF patients. Drug-drug interactions should be analysed in long-term RCTs recruiting diabetic and non-diabetic patients with CVD.
The results of several on-going long-term randomised trials should provide key information on the cardiorenal protective effects of SGLT2Is in different patient populations, their safety profile, which patients are at greatest risk for serious AEs, and possible differences in the efficacy/ safety profile between drugs of this pharmacological class.
